Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Repair Biotechnologies Inc. is managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners, indicating a varied range of review within the USPTO. The busiest examiner, IANNUZO, NATALIE NMN, is currently handling 1 pending action. This suggests that the workload is evenly spread, as no single examiner is managing more than 1 of the company's 2 pending actions. The focus on 2 distinct examiners suggests that the company's current legal strategy involves multiple points of contact.
The portfolio's reach extends across 2 distinct art units, which matches the number of distinct examiners involved. This variety shows that the company's 2 pending office actions involve different technical specialties within the biotechnology sector. For practitioners, this means that the prosecution strategy must be adapted to the specific standards of 2 different art units and 2 different examiners. The presence of 2 pending actions across these units reflects a distributed prosecution profile where each matter is handled by a unique examiner. IANNUZO, NATALIE NMN holds 1 pending action, making their specific examination style a factor in the company's current prosecution outcomes.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 50d overdue |
| 18265376 | ENHANCING MITOCHONDRIAL-BASED FLOW AND CATABOLISM OF CHOLESTEROL | BUTTICE, AUDREY L | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269869 | HEPATOCELLULAR CARCINOMA TREATMENTS, PROPHYLACTIC THERAPIES, AND COMPOSITIONS FOR USE THEREWITH | IANNUZO, NATALIE NMN | 1653 | §102§103 | Final Rejection | 50d overdue | Pending | Jun 27, 2023 |
| 18265376 | ENHANCING MITOCHONDRIAL-BASED FLOW AND CATABOLISM OF CHOLESTEROL | BUTTICE, AUDREY L | 1647 | §103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRepair Biotechnologies Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Natalie Nmn Iannuzo has the most, with 1 of Repair Biotechnologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
